

Registered Office : 815, Nilamber Triumph, Gotri-Vasna Road, Vadodara - 390 007. Gujarat (INDIA). Ph. : +91-265-2991021 / 2991022

Email : admin@pardrugs.com

CIN No.: L24117GJ1999PLC035512

www.pardrugs.com

PAR/CS/NSE/2021-22/59

Date: 15/12/2021

To, The Manager Listing department, **National Stock Exchange of India Limited** Exchange Plaza, C-1, Block-G, Bandra Kurla Complex, Bandra (E), Mumbai- 400 051 Maharashtra

### Symbol - PAR, ISIN: INE04LG01015

- Subject: Investors Presentation
  - Ref.: Regulation 30 read with Schedule III of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

With reference to above captioned subject and pursuant Regulation 30 read with Schedule III of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, we hereby attached our latest Investors Presentation.

You are requested to kindly take note on your record.

Yours Faithfully For PAR DRUGS AND CHEMICALS LIMITED

(Mr. Falgun V. Savani) Managing Director DIN: 00198236

**Encl: Investor Presentation** 





Investor Presentation | December 2021

# <sup>2</sup> Executive Summary



#### Overview



- Incorporated in 1999, Par Drugs and Chemicals Limited (hereinafter referred as "Company" or "PDCL") is engaged in the development and manufacture of Active Pharma Ingredients ("APIs") and Fine Chemicals for the domestic market as well as for exports to international markets.
- The company currently produces the entire range of *Antacid Molecules* and the product portfolio presently comprises 18 APIs and 10 Fine Chemicals.
- The company operates a manufacturing facility at Bhavnagar in Gujarat.
- The company supplies products to approximately 16 countries, including both direct and indirect exports.
- As on March 31, 2021, PDCL caters to more than 132 customers through dealers/agents worldwide. The company has added new 20 clients in FY21.

#### **Business Mix FY21**

- API (64%): The APIs manufactured are purchased by pharmaceutical companies that convert the APIs into various forms of formulations such as tablets and liquid form for final sale, used as an API in Antacid Formulation.
- Fine Chemicals (36%): The company offers Fine Chemicals used as an Antacid Raw material in specific antacid formulations, ceramics, suspending agent, thickening agent, Pesticides & detergents, special low moisture grade, free flow salt & anticaking agent for agriculture and paints space etc.

#### **Financials FY21**

Income – INR 607 MN					
EBITDA – INR 159 MN					
EBITDA – 26.19%					
PAT – INR 116 MN					
PAT – 19.11%					

Company Overview


# Company Overview



# **CPPCP**

- Promoted by Mr. Falgun Savani and Mr. Jignesh Savani, Par Drugs and Chemicals Limited (PDCL) was founded in 1982 and is engaged in the development and manufacturing of APIs.
- The Company today manufactures more than 28 different products and all the requisite grades as available in the market. The product portfolio presently comprises of 18 APIs and 10 Fine Chemicals which are marketed domestically and exported.
- Currently, the company owns and operates a manufacturing facility at Bhavnagar in Gujarat with an annual capacity of 9,700 MT.
- The company is the largest manufacturer of Magnesium Hydroxide, Sucralfate and Magnesium Trisilicate in India.
- Company's key customers include Essential Drugs Company Ltd., Pfizer Ltd., United Phosphorus Ltd., Cipla Ltd., etc.
- PDCL exports its products to approximately 16 countries, including Germany, the United Kingdom, Bangladesh, Iran, and U.A.E etc.
- APIs, also known as "bulk drugs" or "bulk actives" are the principal ingredient used in making finished dosages in the form of capsules, tablets, liquid, or other forms of dosage, with the addition of other APIs or inactive ingredients.

### Operational Revenues (INR Mn)





#### Falgun Vallabhbhai Savani Managing Director

- Holds Bachelor's degree in Pharmacy from B. K. Modi Government Pharmacy College, Rajkot affiliated with Saurashtra University.
- Has 20 years of experience in the API Industry and is playing a vital role in formulating business strategies and effective implementation of the same.
- Responsible for expansion and overall management of the business of our Company and his leadership abilities have been instrumental in leading the core team.

Jignesh Vallabhbhai Savani Executive Director & CEO

- Has completed Matriculation education from Gujarat Secondary Education Board.
- Has 19 years of experience in the API Industry and has been actively involved in the day-to-day operations of the Company and looks after the sales, administration and finance department.

Ghanshayambhai Bhagvanbhai Savani Whole-Time Director

- Has 30 years of experience in the API Industry and his expertise and business acumen helped in sustainable growth.
- Actively engaged in the production activity of the Company.

Pravin Manjibhai Bhayani Independent Director

Kajal Chintanbhai Vaghani Independent Director

Krishna Mitulbhai Shah Independent Director


Nayna Jignesh Savani Non - Executive Director

Bintal Bhaveshkumar Shah Independent Director



# Geographical Presence










#### Mr. V. J. Savani established in the year 1982 in the name of Par Inorganics, later Par Drugs and Chemicals was incorporated in the year 1999.



 Ankleshwer plant was upgraded with spray dryer system

### Research & Development



- Company's focus is on developing non-infringing processes and achieving process improvements and production cost efficiencies.
- The main focus will be to expand the ability to penetrate different applications of current molecules with modified physical and chemical structures.
- In FY21 the company has initiated focus towards R&D on chronic therapies like antidepressants, anti-diabetic and anti-bacterial.
- The laboratory at Chitra, Bhavnagar, is equipped with modern equipments including electronic balances, KF apparatus, ovens, stability chambers, computers, HPLC with IR Detector, Particle Size Analyser, Surface Area Analyser. We also have a dedicated Microbiological Laboratory to perform microbiological tests.





The primary responsibilities of the R&D team include:-

- New products development
- Development of customized products catering to the specific requirement of customers
- Scale up and Optimization of new technologies
- To render assistance to production and quality assurance for quality improvement, troubleshooting in existing process and products
- Value engineering and development of cost-effective process

# Manufacturing Facility





### Manufacturing Facility - Chitra, Bhavnagar, Gujarat

There are four Manufacturing Blocks are for different products having a capacity of 9,700 MTPA.

Block 1 – APIs Block 3 - Fine Chemicals Block 2 - Magnesium Hydroxide Block 4 – APIs/ Fine Chemicals









## Manufacturing Process



SUNTERED STATES	Reaction	Filtration	brying	Quality Control and Sampling	Packaging
Procurement of magnesium chloride, caustic soda lye, soda ash, Aluminium chloride etc. All incoming raw materials are tested as per specifications.	Chemical reaction takes place in a controlled environment between the raw materials. The quantity or raw material and addition of the same depends on the final product to be manufactured.	After the reaction, the slurry has to be washed to remove impurities. Washing process is carried out until the product comply with prescribed limit as per specification. It is a controlled process and sulphates and chlorides are washed off with treated water.	Excess water from the product is evaporated at a controlled temperature and getting the final product in powder form.	The sampling is done for the final product as per the system and norms already defined and then these samples are sent to the QC for testing as per the pharmacopoeia.	The material is sent to the packaging department where it is packed in LDPE and HDPE containers and supplied to various parties.







**Diversified Portfolio:** The company manufactures the entire range of products in the Antacid segment. The product portfolio presently comprises 18 APIs and 10 Fine Chemicals which are marketed domestically and exported.



**Global Presence:** The Company is operating both in domestic and export markets. The export products are to approximately 16 countries, including Germany, United Kingdom, Bangladesh, Iran, and U.A.E, Indonesia, Japan, South Korea, etc.



**Experienced Promoters:** Led by qualified and experienced Promoters and key managerial personnel, who we believe have extensive knowledge and understanding of the APIs business environment and have the expertise and vision to organically scale up the business.



**Robust Chemistry Capabilities:** A research driven Company with R&D efforts focused on developing processes and achieving process improvements and production cost efficiencies.



Diversified Customer base: Catering to more than 191 customers through dealers/agents worldwide.



**Established Sales and distribution network:** Comprising of more than 40 dealers and distribution network is spread globally comprising of 13 agents.



**Cash Rich Company:** The company is a net debt free and generates free cash flow. They plans it expansions through internal accruals.

Business Overview







The company is one of the largest manufacturer in Magnesium Hydroxide, Sucralfate and Magnesium Trisilate in India.

API (	Fine Chemicals (28%)	
Magnesium Hydroxide	Magnesium Oxide USP	Precipitated Silica
Sucralfate	Almagate BP	Sodium Aluminium Silicate
Dried Aluminium Hydroxide Gel	Light Magnesium Carbonate	Amorphous Aluminium Hydroxide
Dhed Aldminium Hydroxide Ger	Light Magnesium Carbonate	PARSIL-HT
Magaldrate	Light Magnesium Carbonate	PAR ADD OP
Magnesium Trisilicate	Colloidal Silicon Dioxide	MagSil OF
Aluminium Magnesium Silicate	Magnesium Aluminometasilicate	FlowSil
Magnesium Aluminosilicate-USP	Magnesium Oxide Light	Aluminium Hydroxide Magnesium Carbonate Co-Dried Gel
Magnesium Oxide Heavy	Magnesium Aluminium Hydrate	Magnesium Aluminium Silicate- Hydrated (Pharma)
Hydrotalcite	Synthetic Aluminium Silicate	Magnesium Aluminium Silicate- Hydrated (Agro)



API

Fine Chemicals

Business Verticals



#### API

- PDCL currently produces the entire range of Antacid Molecules available in the market.
- Antacids are medication that neutralizes stomach acid to cut down on heartburn, sour stomach, acid indigestion, and stomach upset, symptoms of Gastroesophageal Reflux Disease (GERD also called acid reflux), heartburn or indigestion (also called dyspepsia).
- They contain ingredients such as aluminium, calcium, magnesium, or sodium bicarbonate which act as bases (alkalis) to counteract stomach acid and make its pH more neutral.
- Some such products are formulated to minimize such effects through the inclusion of equal concentrations of magnesium hydroxide or magnesium carbonate, which have counterbalancing laxative effects.

#### FINE CHEMICALS

- The company manufactures Fine chemicals that are inorganic molecules produced in kilogram to multiton quantities by conventional or chemical processes.
- Applications that involve the use of fine chemicals include catalysts, adhesives, food, and specialty polymers for advanced composites etc. Similarly, fine chemicals are also employed in the agrochemical industry for manufacturing pesticides, fungicides, and herbicides through rigorously controlled contamination prevention protocols.

# APIs and their Applications



- Widely used as an Antacid in many Formulations helping reduce stomach acid
- Also used as intermediate for obtaining magnesium metal, residual fuel additive, sulfite pulp, uranium processing, dentifrices, in food as alkali, drying agent, colour retention agent, frozen desserts

#### Sucralfate

- It is a medication primarily taken to treat active duodenal ulcers.
- Sucralfate is also used for the treatment of gastroesophageal reflux disease and stress ulcers.

#### Dried Aluminium Hydroxide Gel

- Mainly used as an active medicament in an Antacid Formulations
- Used in manufacturing of lake colours, Inks, catalysts carrier etc.

#### Magaldrate

• It is a common antacid drug that is used for the treatment of duodenal and gastric ulcers, esophagitis from gastroesophageal reflux

#### Magnesium Trisilicate

- Used as Antacid in Antacid Formulations.
- Useful Antioxidant, decolorizing agent
- Industrial odour absorbent

#### Synthetic Aluminium Silicate-KP

• Used in cattle feed product formulation

#### Magnesium Aluminosilicate-USP

• Used as an Antacid Raw material in a specific antacid Formulation

#### Magnesium Aluminometasilicate-KP/USP

• Used as an Antacid Raw material in a specific antacid Formulation

#### Aluminium Magnesium Silicate

- Used as an Antacid Raw material in a specific antacid formulation.
- Ceramics suspending agent, thickening agent etc.

#### Magnesium Oxide USP

• Its uses include relief of heartburn and sore stomach, as an antacid, magnesium supplement and as a short-term laxative

#### Almagate BP

• Used as an Antacid Raw material in specific antacid formulations.

#### Heavy Magnesium Carbonate – IP/BP/UPS

• Used as an Antacid Raw material in a specific antacid Formulation.

#### **Colloidal Silicon Dioxide**

• Has many uses in tablet-making: some include as an anti-caking agent, adsorbent, disintegrate or glidant to allow powder to flow freely when tablets are processed.

#### Hydrotalcite

• Used as an API in Antacid Formulation.

#### Magnesium Aluminium Hydrate

• Used as an Antacid Raw material in a specific antacid Formulation

#### Light Magnesium Carbonate

Light Magnesium Carbonate is an inorganic compound used as a common antacid.

- Used to produce magnesium metal and basic refractory bricks.
- Used in flooring, fire proofing,
- Fire extinguishing compositions,
- Cosmetics, dusting powder and toothpaste.

#### Magnesium Oxide Light

Magnesium Oxide is a common antacid drug that is used for Pharmaceutical aid.

- Filling and reinforcing agent for light-coloured plastic and rubber products.
- Polishing agent, binding agent,
- Accelerator and activator for fluorine and chloroprene rubber.
- For making ceramic, enamel, advanced refractory materials. Used for making magnesium chloride cement. Widely used in glass, dyes, phenolic plastic and other fields.

#### Magnesium Oxide Heavy

- Common Antacid drug used in pharmaceutical aid.
- Widely used as high temperature resistant materials.



# Fine Chemicals and their Applications



Fine chemicals are chemical substances prepared to a very high degree of purity. They can be used in different industries. These chemicals are used for special applications by manufacturing firms that make the following products: Pharmaceuticals, paints, petrochemicals, adhesives and agricultural products.

### **Precipitated Silica**

It is a form of silica (silicon dioxide, SiO2); it is a white, powdery material. Precipitated silica is produced by precipitation from a solution containing silicate salts.

- Pesticides & Detergents
- Special Low Moisture Grade
- Free Flow Salt & Anticaking Agent
- For Cosmetics
- Pharmaceuticals

### Allusil (Sodium All. Silicate) - Sodium Aluminium Silicate

It is a composition of Silicate & Aluminium Salt.

- Paper
- Paint
- Coating application

### Amorphous Aluminium Hydroxide

• Amorphous Aluminium Hydroxide Dried Gel is used in the manufacturing of construction chemicals mainly used to manufacture "Short Crete".

### PARSIL - HT

• Used in Specialized Agro Formulation.

### PAR ADD OP

Used as Filler in PVC Pipes Manufacturing.

### Magnesium Aluminium Silicate (Agro)

• Used as Plant Growth Supplement

### Magnesium Aluminium Silicate (Pharma)

- Used as an Antacid Raw material in a specific antacid Formulation.
- Ceramics, suspending agent, thickening agent etc.

### Aluminium Hydroxide Magnesium Carbonate Co-Dried Gel

• Used as Pharma Excipient in specific antacid formulations.

#### MagSil OF

• Used in Regeneration of Used Cooking Oil

#### **FlowSil**

• Used as Packing Material in Chromatographic Columns

# Future Strategy



#### Expand the product portfolio:

Seek to leverage the R&D capabilities to expand PDCL's Product Portfolio and thus penetrate the different segments of application and value added products. This will ultimately increase the profitability by value addition.

#### Exploring new geographical area:

Intend to continue to grow sales by exploring new geographical area and developing new products portfolio. Currently targetting to enter Japan, South Korea and China.

#### Direct Exports:

With the aim to enhance the growth of the company, the company wishes to serve its customers directly and improve relations.

#### Continuous Research and Development using Innovation:

A new fully owned R&D Centre will be set-up to add new APIs molecules in other therapeutic segments as well like anti-depressants, anti-diabetics and anti-fungal.

#### Expansion:

The Company has completed Brownfield Expansion in March 2021. With the growth in product portfolio, the company plans to do a greenfield expansion in the next two to three years.


Industrial Overview



# API Industry

- More than 30% of the APIs manufactured in India are exported to countries such as US, UK, Japan, etc. The total production market of API in India was valued at approximately USD 11 Bn in FY16. This market is forecasted to grow at a CAGR of around 9% during the period of FY 16–FY22.
- Of the total domestic consumption, approximately 32% was imported. Of the total imports, China accounts for 57-60% of the APIs imported by India. The remaining imports are from countries such as Italy, Germany, Malaysia, and others.
- India is also one of the major exporters of bulk drugs, supplying high-quality bulk drugs to both regulated and semi-regulated markets.
- In terms of industries in India, the manufacturing of pharmaceutical products and medicines has shown the highest growth at 39.5%. And as per item groups, digestive enzymes and antacids showed an uptick of 110.7%.
- 250 Mn in India suffers from the common disease i.e. acidity. Acidity is the result of excess secretion of acids in the gastric glands of the stomach by eating spicy food.
- The propelling factors for the growth of the antacids market include the growing geriatric population suffering from GERD, poor lifestyle choices leading to higher incidences of acidity, and side effects of drugs like non-steroidal, anti-inflammatory drugs.

(Sources: Million Insights, Grand View Research, IBEF, Global news wire, Mordor Intelligence)




Antacids Market - Growth Rate by Region (2018)



# Fine Chemical Industry

- The global Fine Chemicals market is valued at USD 1,55,550 Mn in 2018 and is expected to reach USD 2,19,490 Mn by the end of 2024, growing at a CAGR of 7.1% between 2019 and 2024.
- North America and Europe is the industry's leading region. In 2018, the revenue of Fine Chemicals is about USD 36.17 Bn in North America; its proportion of total global revenue exceeds 23.91%. In 2018, the revenue is about USD 46.31 Bn in Europe. India and China have witnessed a major chunk developing of Fine Chemicals in the Asia region.
- Fine chemicals account for about 4% of the universe of chemicals valued at USD 2,500 Bn and are dominated mainly by oil & gas and mineral-derived commodities (~40%) on one hand and a large variety of specialty chemicals on the other hand (~55%).
- The global production value of fine chemicals is estimated at USD 85 Bn, of which about 2/3 or USD 55 Bn are produced captively and USD 30 Bn represent the global revenues of the fine chemical industry. The corresponding figures for the major user, the pharmaceutical industry, are USD 32 Bn and USD 23 Bn, respectively.
- On the basis of end-users, the fine chemicals market is segmented into pharmaceuticals, agro chemicals, polymer additives, food and feed, electronics, dyes and pigments, perfumes and fragrances, and others. Fine chemicals are used in many industries like agrochemicals and perfumes & fragrances are also the major end-user segments, which are occupying prominent share among all other applications after pharmaceuticals.
- To elaborate, Agrochemical companies are the second largest users of fine chemicals. As a consequence of an intensive M&A activity over the past two decades, the industry now is more consolidated than the pharmaceutical industry.





(Source: Reuters.com, Market Watch, www.essentialchemicalindustry.org)

Financial Overview 24

10.85

MAY JUN JUL





Income Statement (INR Mn)	FY19	FY20	FY21	H1-FY22
Income from Operations	463	558	607	361
Total Expenses	381	464	448	279
EBITDA	82	94	159	82
EBITDA Margin	17.71%	16.85%	26.19%	22.71%
Finance Cost	20	8	6	3
Depreciation	30	27	28	17
Other Income	1	1	2	1
Profit before Extra Ordinary Items	33	60	127	63
Extraordinary items	-	-	(20)	-
Profit Before Tax	33	60	147	63
Тах	8	12	31	16
Profit after tax	25	48	116	47
PAT Margin	5.40%	8.60%	19.11%	13.02%
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	25	48	116	47
Diluted EPS (INR)	5.60	7.75	18.87	3.8


### <sup>23</sup> Balance Sheet (IND-AS)



EQUITIES & LIABILITIES (INR Mn)	FY20	FY21	H1-FY22	ASSETS (INR Mn)	FY20	FY21	H1-FY22
Shareholder Funds	406	523	569	Non Current Assets	359	352	352
(A) Equity Share Capital	61	62	123	(A) Fixed Assets			
(B) Reserves & Surplus	345	461	446	(i) Tangible Assets	344	299	344
				(ii) Capital work-in-progress	7	45	-
Non-current Liabilities	87	82	78	(B) Non Current Investments	1	-	-
(A) Long Term borrowings	46	44	40	(C) Long Term Loans & Advances	7	8	8
(B) Deferred Tax Liabilities (net)	37	34	34				
(C) Long term Provisions	4	4	4				
Current Liabilities	108	159	89	Current Assets	242	412	384
(A) Short term borrowings	-	32	-	(A)Inventories	29	30	30
(B) Trade Payables	62	67	57	(B) Trade Receivables	124	125	141
(C) Other Current Liabilities	27	25	13	(C) Cash & cash equivalents	74	212	179
(D) Short term Provisions	19	35	19	(D) Short Term Loans & Advances	6	-	-
				(E) Other Current Assets	9	45	34
GRAND TOTAL - EQUITIES & LIABILITES	601	764	736	GRAND TOTAL – ASSETS	601	764	736

<sup>24</sup> Financial Highlights







# <sup>25</sup> Capital Market Highlights



Price Data (30th September, 2021)	INR
Face Value	10.0
Market Price	210.45
52 Week High/Low	210.45/49.00
Market Cap (Mn)	2,589.5
Equity Shares Outstanding (Mn)**	12.3
1 Year Avg Trading Volume ('000)	23.8





\*\* Issue of Bonus shares in the ratio of 1:1 on 30<sup>th</sup> April, 2021





#### Par Drugs and Chemicals Limited:

The above Presentation with slides have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company. This Presentation has been prepared based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied. whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of or any omission from, this Presentation is expressly excluded. All actions and statements made herein or otherwise shall be subject to the applicable laws and regulations as amended from time to time. There is no representation that all information relating to the context has been taken care off in the presentation and neither we undertake any obligation as to the regular updating of the information as a result of new information, future events or otherwise. We will accept no liability whatsoever for any loss arising directly or indirectly from the use of, reliance of any information contained in this presentation or for any omission of the information. The information shall not be distributed or used by any person or entity in any jurisdiction or countries were such distribution or use would be contrary to the applicable laws or Regulations. It is advised that prior to acting upon this presentation independent consultation / advise may be obtained and necessary due diligence. investigation etc may be done at your end. You may also contact us directly for any questions or clarifications at our end. This presentation contain certain statements of future expectations and other forward-looking statements, including those relating to our general business plans and strategy, our future financial condition and growth prospects, and future developments in our industry and our competitive and regulatory environment. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections. In addition to statements which are forward looking by reason of context, the words 'may, will, should, expects, plans, intends, anticipates, believes, estimates, predicts, potential or continue and similar expressions identify forward looking statements. Actual results, performances or events may differ materially from these forwardlooking statements including the plans, objectives, expectations, estimates and intentions expressed in forward looking statements due to a number of factors, including without limitation future changes or developments in our business, our competitive environment, telecommunications technology and application, and political, economic, legal and social conditions in India. It is cautioned that the foregoing list is not exhaustive This presentation is not being used in connection with any invitation of an offer or an offer of securities and should not be used as a basis for any investment decision.

#### Valorem Advisors Disclaimer:

Valorem Advisors is an Independent Investor Relations Management Service company. This Presentation has been prepared by Valorem Advisors based on information and data which the Company considers reliable, but Valorem Advisors and the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Valorem Advisors also hereby certifies that the directors or employees of Valorem Advisors do not own any stock in personal or company capacity of the Company under review.

#### For further details, please feel free to contact our Investor Relations Representatives:



Mr. Anuj Sonpal Valorem Advisors Tel: +91-22-4903-9500 Email: pardrugs@valoremadvisors.com

